Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real‐world finding
Article in Immunity Inflammation and Disease (February 2024)
The most recent citing publications are shown below. View all 22 publications that cite this research output on Dimensions.
Assessment of Wnt-5a, Anti-SMA, FGF-23, and Anti-CCP Biomarkers in Patients with Rheumatoid Arthritis
Article in Journal of Zankoy Sulaimani - Part A (December 2023)
Serum CDC42 is increased during tumor necrosis factor inhibitor treatment, and its elevation correlates with satisfactory treatment response in rheumatoid arthritis patients
Article in International Journal of Rheumatic Diseases (June 2023)